School of Medicine
Showing 1-8 of 8 Results
-
Arnav Mehta, MD, PhD
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDr. Mehta is a board-certified, fellowship-trained medical oncologist at the Stanford Medicine Cancer Center. He is also an adjunct clinical assistant professor in the gastrointestinal (GI) oncology group of the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Mehta specializes in gastrointestinal cancer, with a particular focus on pancreatic and gastric cancers. He also treats colorectal cancers. His treatment specialties include immunotherapy — helping a patient’s immune system fight cancer — and targeted therapies, which send cancer-fighting drugs to specific cancer cell molecules.
His research interests include understanding why GI cancers resist treatments and identifying new ways to treat these tumors. In particular, he is interested in GI tumor immunology, which focuses on directing a person’s immune system to help destroy cancer cells. He also has a special interest in tumor plasticity, which represents the ability of a tumor cell to evolve and develop resistance to therapies.
Dr. Mehta has earned research awards and grants from organizations including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the National Institutes of Health.
Dr. Mehta has published in many peer-reviewed journals, including Nature, Nature Genetics, Nature Immunology, Nature Medicine, Nature Cancer, Cancer Discovery and Immunity. He has written book chapters on subjects including esophageal and gastric cancer. He has also presented his research on topics including tumor immunology and pancreatic cancer at dozens of symposia and meetings around the country.
Dr. Mehta is a member of the AACR and ASCO. -
Beverly S. Mitchell, M.D.
George E. Becker Professor of Medicine, Emerita
Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.
-
Eric Mou, MD
Postdoctoral Medical Fellow, Oncology
BioI was born in Oregon and raised in Iowa, where I cultivated my initial interest in science and medicine. I completed my undergraduate degree and medical school at the University of Iowa before heading to Stanford University for my internal medicine residency and oncology fellowship training. I chose this field to try my best in assisting patients during times of great need, and working to understand what is of greatest importance to them as they navigate their unique journey of cancer care. My clinical focus is in the care of patients with lymphoma and other hematologic cancers. My scholarly interests include better understanding the efficacy cancer therapeutics, improving patients' experience as the proceed through treatment, and promoting strength in medical education.